Form D · Pharmaceuticals
TORL Biotherapeutics LLC
Culver City, CA · CIK 0001797180
Offering snapshot reported Apr 17, 2024 · SEC filing
- Reported sold
- $158M Offering amount: $158M
- Investors reported
- 52 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 4, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 17, 2024 | Initial | $158,300,000 | No comparison | 52 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-510814
Source: Form D, filed Apr 17, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Alles | Director, Executive |
| Mark Attanasio | Director |
| David Licata | Director, Executive |
| Neil O'brien | Director |
| Lynn Seely | Director |
| Amit Sinha | Director |
| Dennis Slamon | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
6100 Bristol Parkway
Culver City, CA, 90230
Culver City, CA, 90230